非生发中心弥漫大B细胞淋巴瘤研究进展

Research progress of non germinal center of diffuse large B cell lymphoma

弥漫大B细胞淋巴瘤（DLBCL）是成人淋巴瘤中最常见的一种类型,其发病率占非霍奇金淋巴瘤的31%-34%。DLBCL发病率在亚洲国家一般大于40%。根据基因芯片技术和免疫组织化学技术,可将DLBCL分为生发中心型（GCB）和非生发中心型（non-GCB）两类,non-GCB型较多见且预后差,本文将对non-GCB型的分子发病机制和治疗进展进行综述总结。

Diffuse large B cell lymphoma is the most common type of non-Hodgkin lymphoma. With the development of microarray and immunohistochemistry,diffuse large B cell lymphoma is subdivided into the germinal center B-cell-like （GCB） and non germinal center B-cell-like （non-GCB）. The majority of domestic and foreign studies suggest that treatment efficacy of non-GCB type is far worse than that of GCB type. Recently the molecular pathogenesis of non-GCB type has been explored and related molecular targets have become clear. Lenalidomide, bortezomid and ibrutinib are expected to improve treatment efficacy of non-GCB type.